BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has withdrawn its Kyndrisa (drisapersen) Marketing Authorization Application (MAA) from the European ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE